Growth Stock With Analysts Upside: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Research brokerages are projecting Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to grow at an accelerated rate over the next 5 years.  Wall Street analysts are looking for the company to grow 37.58% over the next year and 35.00% over the next five years.

Ligand Pharmaceuticals Incorporated’s trailing 12- months EPS is -0.18.  Last year, their EPS growth was -101.00% and their EPS growth over the past five years was -17.40%.  

Let’s start off by taking a look at how the stock has been performing recently.  Over the past twelve months, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)’s stock was 14.90%.  Last week, it was -1.23%, 10.63% over the last quarter, and  10.54% for the past half-year. 

Over the past 50 days, Ligand Pharmaceuticals Incorporated stock was -5.76% off of the high and 12.47% removed from the low.  Their 52-Week High and Low are noted here.  -16.12% (High), 34.00%, (Low). 

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)’s performance this year to date is 14.90%.  The stock has performed -1.23% over the last seven days, 1.89% over the last thirty, and 10.63% over the last three months.  Over the last six months, Ligand Pharmaceuticals Incorporated’s stock has been 10.54% and -7.36% for the year.

Wall Street analysts are have a consensus analyst recommendation of 2.00 on the stock.  This is based on a 1-5 scale where 1 represents a Strong Buy and 5 a Strong Sell.  Brokerages covering the name have a $132.50 on the stock.

The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs.  Where quoted, past performance is not indicative of future performance.

Leave a Comment